{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-295027","form_type":"8-K","ticker":"AMGN","cik":"0000318154","company_name":"AMGEN INC","filed_at":"2023-12-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.629957+00:00","generated_at":"2026-06-07T13:09:05.357276+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Amgen names James Bradner as EVP R&D/CSO; David Reese transitions to CTO","bullets":["James Bradner, formerly President of Novartis Institutes for BioMedical Research, joins as EVP R&D and CSO effective Dec 18, 2023.","David M. Reese moves from EVP R&D to newly created EVP and Chief Technology Officer role effective Dec 18, 2023.","Both executives report to Chairman and CEO Robert A. Bradway.","Reese will lead acceleration of AI and technology across Amgen; he was key architect of Amgen's AI initiatives.","Announcement made Dec 14, 2023; appointments underscore Amgen's push to converge biotech and tech."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-295027","json":"https://secwatch.observer/filing/0001193125-23-295027.json","markdown":"https://secwatch.observer/filing/0001193125-23-295027.md","text":"https://secwatch.observer/filing/0001193125-23-295027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318154/000119312523295027/0001193125-23-295027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318154/000119312523295027/d598661d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T13:09:05.357276+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3278dcd47f","claim":"James Bradner was appointed as Executive Vice President, Research and Development, and Chief Scientific Officer at AMGEN INC.","evidence_excerpt":"James Bradner, M.D., has been hired as the Company’s Executive Vice President, Research and Development, and Chief Scientific Officer, an executive officer position.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/318154/000119312523295027/0001193125-23-295027-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"hired"},{"label":"Role","value":"Executive Vice President, Research and Development, and Chief Scientific Officer"}],"fact_type":"executive_change"},{"claim_id":"9ab5749bb1","claim":"David M. Reese changed role as Executive Vice President and Chief Technology Officer at AMGEN INC.","evidence_excerpt":"David M. Reese, M.D., will transition from Executive Vice President, Research and Development to Executive Vice President and Chief Technology Officer, a newly created executive officer position, responsible for accelerating the use of technology and artificial intelligence (AI) across all facets of Amgen Inc.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/318154/000119312523295027/0001193125-23-295027-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"transition"},{"label":"Role","value":"Executive Vice President and Chief Technology Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}